1-12 of 12
Garry Schwartz
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies

Bahram Forouzesh, Manuel Hidalgo, Quincy Chu, Alain Mita, Monica Mita, Garry Schwartz, José Jimeno, Javier Gómez, Vicente Alfaro, Claudia Lebedinsky, Patrik Zintl, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (10): 3591–3599.
https://doi.org/10.1158/1078-0432.CCR-08-2889
Published: 18 May 2009
View article titled, Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies
Open the PDF for Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies in another window
Journal Articles

Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study

Alejandro D. Ricart, Anthony W. Tolcher, Glenn Liu, Kyle Holen, Garry Schwartz, Mark Albertini, Geoffrey Weiss, Salim Yazji, Chee Ng, George Wilding
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (23): 7924–7929.
https://doi.org/10.1158/1078-0432.CCR-08-0378
Published: 01 December 2008
View article titled, Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α<sub>5</sub>β<sub>1</sub> Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study
Open the PDF for Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α<sub>5</sub>β<sub>1</sub> Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study in another window
Journal Articles

A Phase I and Pharmacokinetic Study of Pemetrexed Plus Irinotecan in Patients with Advanced Solid Malignancies

Eric K. Rowinsky, Muralidhar Beeram, Lisa A. Hammond, Garry Schwartz, Johann De Bono, Baharam Forouzesh, Quincy Chu, Jane E. Latz, Shengyan Hong, William John, Binh Nguyen
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (2): 532–539.
https://doi.org/10.1158/1078-0432.CCR-06-1606
Published: 25 January 2007
View article titled, A Phase I and Pharmacokinetic Study of Pemetrexed Plus Irinotecan in Patients with Advanced Solid Malignancies
Open the PDF for A Phase I and Pharmacokinetic Study of Pemetrexed Plus Irinotecan in Patients with Advanced Solid Malignancies in another window
Journal Articles

Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors

Amita Patnaik, Debra Wood, Anthony W. Tolcher, Marta Hamilton, Jeffrey I. Kreisberg, Lisa A. Hammond, Garry Schwartz, Muralidhar Beeram, Manuel Hidalgo, Monica M. Mita, Julie Wolf, Paul Nadler, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (24): 7406–7413.
https://doi.org/10.1158/1078-0432.CCR-06-1886
Published: 22 December 2006
View article titled, Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors
Open the PDF for Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors in another window
Journal Articles

A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer

Anthony W. Tolcher, Kim Chi, John Kuhn, Martin Gleave, Amita Patnaik, Chris Takimoto, Garry Schwartz, Ian Thompson, Kristin Berg, Susan D'Aloisio, Nevin Murray, Stanley R. Frankel, Elzbieta Izbicka, Eric Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (10): 3854–3861.
https://doi.org/10.1158/1078-0432.CCR-04-2145
Published: 16 May 2005
View article titled, A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer
Open the PDF for A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer in another window
Journal Articles

A Phase I and Pharmacokinetic Study of Col-3 (Metastat), an Oral Tetracycline Derivative with Potent Matrix Metalloproteinase and Antitumor Properties

Samira Syed, Chris Takimoto, Manuel Hidalgo, Jinee Rizzo, John G. Kuhn, Lisa A. Hammond, Garry Schwartz, Anthony Tolcher, Amita Patnaik, S. Gail Eckhardt, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (19): 6512–6521.
https://doi.org/10.1158/1078-0432.CCR-04-0804
Published: 08 October 2004
View article titled, A Phase I and Pharmacokinetic Study of Col-3 (Metastat), an Oral Tetracycline Derivative with Potent Matrix Metalloproteinase and Antitumor Properties
Open the PDF for A Phase I and Pharmacokinetic Study of Col-3 (Metastat), an Oral Tetracycline Derivative with Potent Matrix Metalloproteinase and Antitumor Properties in another window
Journal Articles

Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine S-1 on a Once-Daily-for-28-Day Schedule in Patients with Advanced Malignancies

Quincy Siu-Chung Chu, Lisa A. Hammond, Garry Schwartz, Leonel Ochoa, Sun-Young Rha, Louis Denis, Kathleen Molpus, Brian Roedig, Stephen P. Letrent, Bharat Damle, Arthur P. DeCillis, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (15): 4913–4921.
https://doi.org/10.1158/1078-0432.CCR-04-0469
Published: 05 August 2004
View article titled, Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine S-1 on a Once-Daily-for-28-Day Schedule in Patients with Advanced Malignancies
Open the PDF for Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine S-1 on a Once-Daily-for-28-Day Schedule in Patients with Advanced Malignancies in another window
Journal Articles

A Phase I Pharmacokinetic and Biological Correlative Study of Oblimersen Sodium (Genasense, G3139), an Antisense Oligonucleotide to the Bcl-2 mRNA, and of Docetaxel in Patients with Hormone-Refractory Prostate Cancer

Anthony W. Tolcher, John Kuhn, Garry Schwartz, Amita Patnaik, Lisa A. Hammond, Ian Thompson, Howard Fingert, David Bushnell, Shazli Malik, Jeffrey Kreisberg, Elzbieta Izbicka, Leslie Smetzer, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (15): 5048–5057.
https://doi.org/10.1158/1078-0432.CCR-03-0701
Published: 05 August 2004
View article titled, A Phase I Pharmacokinetic and Biological Correlative Study of Oblimersen Sodium (Genasense, G3139), an Antisense Oligonucleotide to the Bcl-2 mRNA, and of Docetaxel in Patients with Hormone-Refractory Prostate Cancer
Open the PDF for A Phase I Pharmacokinetic and Biological Correlative Study of Oblimersen Sodium (Genasense, G3139), an Antisense Oligonucleotide to the Bcl-2 mRNA, and of Docetaxel in Patients with Hormone-Refractory Prostate Cancer in another window
Journal Articles

A Phase I and Pharmacokinetic Study of ILX-295501, an Oral Diarylsulfonylurea, on a Weekly for 3 Weeks Every 4-Week Schedule in Patients with Advanced Solid Malignancies

Bahram Forouzesh, Chris H. Takimoto, Andrew Goetz, Sami Diab, Lisa A. Hammond, Leslie Smetzer, Garry Schwartz, Robert Gazak, John T. Callaghan, Daniel D. Von Hoff, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (15): 5540–5549.
Published: 03 December 2003
View article titled, A Phase I and Pharmacokinetic Study of ILX-295501, an Oral Diarylsulfonylurea, on a Weekly for 3 Weeks Every 4-Week Schedule in Patients with Advanced Solid Malignancies
Open the PDF for A Phase I and Pharmacokinetic Study of ILX-295501, an Oral Diarylsulfonylurea, on a Weekly for 3 Weeks Every 4-Week Schedule in Patients with Advanced Solid Malignancies in another window
Journal Articles

A Phase I, Pharmacokinetic, and Biological Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with Gemcitabine in Patients with Advanced Malignancies

Amita Patnaik, S. Gail Eckhardt, Elzbieta Izbicka, Anthony A. Tolcher, Lisa A. Hammond, Chris H. Takimoto, Garry Schwartz, Heather McCreery, Andrew Goetz, Masataka Mori, Kazutoyo Terada, Lou Gentner, Mary-Ellen Rybak, Henry Richards, Steven Zhang, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (13): 4761–4771.
Published: 27 October 2003
View article titled, A Phase I, Pharmacokinetic, and Biological Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with Gemcitabine in Patients with Advanced Malignancies
Open the PDF for A Phase I, Pharmacokinetic, and Biological Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with Gemcitabine in Patients with Advanced Malignancies in another window
Journal Articles

A Phase I and Pharmocokinetic Study of Exatecan Mesylate Administered as a Protracted 21-Day Infusion in Patients with Advanced Solid Malignancies

Mitchell A. Garrison, Lisa A. Hammond, Charles E. Geyer, Jr., Garry Schwartz, Anthony W. Tolcher, Leslie Smetzer, Jose A. Figueroa, Murray Ducharme, John Coyle, Chris H. Takimoto, Robert L. De Jager, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (7): 2527–2537.
Published: 01 July 2003
View article titled, A Phase I and Pharmocokinetic Study of Exatecan Mesylate Administered as a Protracted 21-Day Infusion in Patients with Advanced Solid Malignancies
Open the PDF for A Phase I and Pharmocokinetic Study of Exatecan Mesylate Administered as a Protracted 21-Day Infusion in Patients with Advanced Solid Malignancies in another window
Journal Articles

A Phase I and Pharmacokinetic Study of 1843U89, a Noncompetitive Inhibitor of Thymidylate Synthase, in Patients with Advanced Solid Malignancies

Garry Schwartz, Thomas R. Johnson, Andrew Goetz, Howard Burris, Leslie Smetzer, Thomas Lampkin, Jeffrey Sailstad, John A. Hohneker, Daniel D. Von Hoff, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (7): 1901–1911.
Published: 01 July 2001
View article titled, A Phase I and Pharmacokinetic Study of 1843U89, a Noncompetitive Inhibitor of Thymidylate Synthase, in Patients with Advanced Solid Malignancies
Open the PDF for A Phase I and Pharmacokinetic Study of 1843U89, a Noncompetitive Inhibitor of Thymidylate Synthase, in Patients with Advanced Solid Malignancies in another window